Review and cross-validation of gene expression signatures and melanoma prognosis

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 274-283

  Schramm, Sarah Jane ^a   Campain, Anna E ^b   Scolyer, Richard A ^a,c,d   Yang, Yee Hwa ^b   Mann, Graham J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; OSTEOPONTIN; RAS PROTEIN;

BIOINFORMATICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DISTANT METASTASIS FREE SURVIVAL; DNA REPLICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; METHYLATION; MICROARRAY ANALYSIS; MITOSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84855947682     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.305     Document Type: Review

References (54)

1. Alexe G, Monaco J, Doyle S et al. (2009) Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging. Exp Biol Med 234:860-79
2. Allison DB, Cui XQ, Page GP et al. (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7:55-65 (Pubitemid 41828948)
3. Arkenau HT, Kefford R, Long GV (2010) Targeting BRAF for patients with melanoma. Br J Cancer 104:392-8
4. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-48 (Pubitemid 32786276)
5. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
6. Bedognetti D, Wang E, Sertoli MR et al. (2010) Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 9:555-65
7. Bittner M, Meitzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-40 (Pubitemid 30625740)
8. Bogunovic D, O'Neilla DW, Belitskaya-Levya I et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106: 20429-34
9. Conway C, Mitra A, Jewell R et al. (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939-46
10. Dalton JE, Kattan MW (2010) Recent advances in evaluating the prognostic value of a marker. Scand J Clin Lab Invest 70:59-62
11. Djebbari A, Quackenbush J (2008) Seeded Bayesian Networks: constructing genetic networks from microarray data. BMC Syst Biol 2:1-13
12. Faratian D, Clyde RG, Crawford JW et al. (2009) Systems pathology-taking molecular pathology into a new dimension. Nat Rev Clin Oncol 6: 455-64
13. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19
14. Gajewski TF, Louahed J, Brichard VG (2010) Gene signature in melanoma associated with clinical activity a potential clue to unlock cancer immunotherapy. Cancer J 16:399-403
15. Glud M, Klausen M, Gniadecki R et al. (2009) MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol 129:1219-24
16. Gould Rothberg BE, Berger AJ, Molinaro AM et al. (2009a) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27:5772-80
17. Gould Rothberg BE, Bracken MB, Rimm DL (2009b) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452-74
18. Han J-DJ (2008) Understanding biological functions through molecular networks. Cell Res 18:224-37
19. Han M-J, Wang H, Beer LA et al. (2010) A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics 10:4450-62
20. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
21. Haqq C, Nosrati M, Sudilovsky D et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-7 (Pubitemid 40594260)
22. Hawkins RD, Hon GC, Ren B (2010) Next-generation genomics: an integrative approach. Nat Rev Genet 11:476-86
23. Hoek KS (2007) DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigm Cell Res 20:466-84 (Pubitemid 47568833)
24. John T, Black MA, Toro TT et al. (2008) Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14: 5173-80
25. Jönsson G, Busch C, Knappskog S et al. (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16:3356-67
26. Jukic DM, Rao UNM, Kelly L et al. (2010) Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 8:23
27. Kannengiesser C, Spatz A, Michiels S et al. (2008) Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol 1:425-30
28. Kauffmann A, Rosselli F, Lazar V et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27:565-73 (Pubitemid 351158908)
29. Kefford R, Arkenau H, Brown MP et al. (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s
30. Kreeger PK, Lauffenburg DA (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31:2-8
31. Kreizenbeck GM, Berger AJ, Subtil A et al. (2008) Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 17:949-58 (Pubitemid 351536428)
32. Lee JH, Choi JW, Kim YS (2010) Frequencies of BRAF and NRAS mutations are different in histologic types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776-84
33. Madabhushi A, Lucas D, Rodriguez-Canales J et al. (2011) Computer aided diagnostic tools aim to empower rather than replace pathologists: lessons learned from computational chess. J Pathol Inform 2:25-7
34. Mandruzzato S, Callegaro A, Turcatel G et al. (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4:1-11
35. Mann GJ, Pupo GM, Campain AE et al. (2010) BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma. Pigment Cell Melanoma Res 23:6
36. Paik S, Shak S, Tang G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-26 (Pubitemid 40051905)
37. Payette MJ, Katz M, Grant-Kels JM (2009) Melanoma prognostic factors found in the dermatopathology report. Clin Dermatol 27:53-74
38. Pepe MS, Feng Z, Janes H et al. (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432-8
39. Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-52
40. Philippidou D, Schmitt M, Moser D et al. (2010) Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 70:4163-73
41. Piras F, Perra MT, Murtas D et al. (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20:271-7
42. Polak ME, Borthwick NJ, Jager MJ et al. (2009) Melanoma vaccines-the problems of local immunosuppression. Hum Immunol 70:331-9
43. Schramm S-J, Mann GJ (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10:1520-8
44. Shendure J (2008) The beginning of the end for microarrays? Nat Methods 5:585-7 (Pubitemid 351911858)
45. Shimokawa K, Mogushi K, Shoji S et al. (2010) iCOD: an integrated clinical omics database based on the systems-pathology view of disease. BMC Genomics 11:S19
46. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464-74
47. Taylor IW, Linding R, Warde-Farley D et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27:199-204
48. Thompson JF, Scolyer RA, Kefford RF (2009) Cutaneous melanoma in the era of molecular profiling. Lancet 374:362-5
49. Timar J, Gyorffy B, Raso E (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27:371-87
50. Tinker AV, Boussioutas A, Bowtell DDL (2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9: 333-9 (Pubitemid 43668729)
51. van't Veer LJ, Dai HY, van de Vijver MJ et al. (2002), Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6.
52. Varmus H (2010) Ten years on-the human genome and medicine. N Engl J Med 362:2028-9
53. Weigelt B, Baehner FL, Reis JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220:263-80
54. Winnepenninckx VR, Lazar V, Michiels S et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-82